Balili and Barkan [9] evaluated hormonal effects of the SERM tamoxifen in 15 male acromegaly patients with active disease and 2 post-menopausal women, also with biochemically-active acromegaly despite the fact that other modalities were ineffective in normalizing their IGF-1 levels. Here, IGF1 is linked to acromegaly.